Tufts CSDD Impact Reports

Analysis and insight into critical drug development issues. Cutting edge information. Original research. Your most reliable guide to drug development.

Tufts CSDD Impact Reports
are a bi-monthly subscription-based publication presenting original research, analysis, and insights on a broad variety of topics, ranging from Tufts CSDD’s current drug development metrics analyses, to global pharmaceutical reimbursement policies. Research presented in Tufts CSDD Impact Reports have been cited in the Boston Globe, Wall Street Journal, Forbes, Time magazine, and the New England Journal of Medicine, among others.

Tufts CSDD Impact Reports are four pages by design.

Critical information made readily accessible:

  • Charts and tables present key points, letting you focus on major findings.

  • Clear, concise—and brief—bulleted items highlight key findings,
    saving you time deciphering extensive text.

  • Explanatory sidebars and definitions ensure a shared understanding of
    key concepts and terms.

Delivery Process.

Orders are processed manually within 24 hours of receipt, during the regular business hours of 9:00 AM - 5:00 PM (EST) Monday - Friday, excluding university holidays. Orders placed outside of business hours will be processed on the following business day. Reports are sent as an electronic attachment (PDF) along with an email receipt. If you do not receive your report within 24 hours, please contact us at csdd@tufts.edu.


Single Issue

Tufts CSDD Impact Report Single (1) Issue: $130 USD
One (1) Issue, Electronic PDF Delivery
Purchase Single Issue

Annual Individual Subscriptions

Tufts CSDD Impact Report Annual Individual Subscription: $515 USD
Details: Six (6) Bi-monthly Issues, Electronic PDF Delivery
Purchase Individual Subscription

Corporate Multi-User Subscriptions

Tufts CSDD offers both individual and corporate subscriptions to Tufts CSDD Impact Reports. Corporate subscriptions provide everyone in your department or organization immediate access to these timely reports. Priced to be cost effective, corporate subscriptions offer a significant volume discount off the annual individual subscription fee. For more information, please contact us by emailing us at csdd@tufts.edu.
Purchase Corporate Multi-User Subscription

Impact Report 2.png

Tufts CSDD Impact Reports 1999-2011

Explore the electronic archive of Tufts CSDD Impact Reports from 1999 - 2011.
View Catalog

Tufts CSDD Impact Report Summaries


Cancer drug approvals grew from 4% of U.S. total in the 1980s to 27% in 2010-18
September/October Vol. 21 No. 5
SUMMARY | Press Release

Growth in rare disease R&D in challenging development strategy and execution
July/August Vol. 21 No. 4
SUMMARY | Press Release

Adoption of artificial intelligence is high across drug development
May/June Vol. 21 No. 3
SUMMARY | Press Release

Outsourcing outpaces internal spending but remains tactical and reactive
March/April Vol. 21 No. 2
SUMMARY | Press Release

U.S. continues to lead new drug R&D, but Asia-Pacific is starting to rise
January/February Vol. 21 No. 1
SUMMARY | Press Release


Global Biotech Product Development Continues its Multi-Decade Surge
November/December Vol. 20 No. 6
SUMMARY | Press Release

CNS Drugs Take 20% Longer to Develop and to Approve vs. Non-CNS Drugs
September/October Vol. 20 No. 5
SUMMARY | Press Release

Rising Protocol Complexity is Hindering Study Performance, Cost, and Efficiency
July/August, Vol. 20 No. 4
SUMMARY | Press Release

Patent-to-launch Time for Orphan Drugs is 2.3 Years Longer vs. Other Drugs
May/June, Vol. 20 No. 3
SUMMARY | Press Release

Clinical Site Initiation Process Remains Lengthy and Highly Inefficient
March/April, Vol. 20 No. 2
SUMMARY | Press Release

Clinical Data Volume and Diversity Pose Increasing Challenges and Delays
Jan/Feb, Vol. 20 No. 1
SUMMARY | Press Release


Real World Evidence Use in Clinical & Post-Approval Research Set to Expand
Nov/Dec, Vol. 19 No.6
SUMMARY | Press Release

Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose
Sep/Oct, Vol. 19 No.5
SUMMARY | Press Release

Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies
Jul/Aug, Vol. 19 No. 4
SUMMARY | Press Release

Biotech Products Accounted for 35% of All New FDA Approvals in 2000-16
May/Jun, Vol. 19 No. 3
SUMMARY | Press Release

Approval Time for 505(b)(2) Drugs is Nearly Five Months Longer Than for NMEs
Mar/Apr, Vol. 19 No. 2
SUMMARY | Press Release

Poor Physician and Nurse Engagement Driving Low Patient Recruitment
Jan/Feb, Vol. 19 No. 1
SUMMARY | Press Release


Pediatric Regulatory Science, Clinical Trial Networks Hold Promise for Studies
Nov/Dec, Vol. 18 No. 6
SUMMARY | Press Release

Diabetes Drug Development is Riskier Compared to All Drug Development
Sep/Oct, Vol. 18 No. 5
SUMMARY | Press Release

Global Regenerative Medicine Market is Poised for Strong Growth
Jul/Aug, Vol. 18 No. 4
SUMMARY | Press Release

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers
May/June, Vol. 18 No. 3
SUMMARY | Press Release

Promise of Immuno-Oncology Therapies is Boosting R&D Funding, Alliances
March/April, Vol. 18 No. 2
SUMMARY | Press Release

Amendments Reduce Number of Patients, But at High Cost, Longer Study Times
January/February, Vol. 18 No. 1
SUMMARY | Press Release


First-in-Class Drugs in Competitive Development Races With Later Entrants
November/December, Vol. 17 No. 6
SUMMARY | Press Release

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy
September/October, Vol. 17 No.5
SUMMARY | Press Release

Vaccine Products in the R&D Pipeline Have More Than Tripled Since 2005
July/August 2015, Vol. 17 No. 4
SUMMARY | Press Release

Personalized Medicine Gains Traction But Still Faces Multiple Challenges
May/June 2015, Vol. 17 No. 3
SUMMARY | Press Release

Biosimilars Entering the U.S. Market Are Likely to Face Multiple Challenges
March/April 2015, Vol. 17 No. 2
SUMMARY | Press Release

High Turnover, Protocol Noncompliance Plague the Global Site Landscape
January/February 2015, Vol. 17 No. 1
SUMMARY | Press Release


CNS Drugs Take Longer to Develop, Have Lower Success Rates, Than Other Drugs
November/December 2014, Vol. 16 No. 6
SUMMARY | Press Release

Protocol Design Optimization Starting to Improve Study Performance
September/October 2014, Vol. 16 No. 5
SUMMARY | Press Release

Patients Face New Challenges Accessing a Growing Number of Orphan Drugs
July/August 2014, Vol. 16 No. 4
SUMMARY | Press Release

Collaboration & Risk-Sharing Programs Experience Longer Development Times
May/June 2014, Vol. 16 No. 3
SUMMARY | Press Release

Drug Sponsors Tread Cautiously Using Social Media to Aid Clinical Research
March/April 2014, Vol. 16 No. 2
SUMMARY | Press Release

New Breakthrough Therapy Designation Program Aims to Cut Clinical Trial Time
January/February 2014, Vol. 16 No. 1
SUMMARY | Press Release


Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically
November/December 2013, Vol. 15 No. 6
SUMMARY | Press Release

Causes of Clinical Failures Vary Widely by Therapeutic, Phase of Study
September/October 2013, Vol. 15 No. 5
SUMMARY | Press Release

Annual Approvals for Neglected Diseases Rose from 2.6 in 2000-08 to 5 in 2009-12
July/August 2013, Vol. 15 No. 4
SUMMARY | Press Release

Clinical Success Rates for New Cancer Drugs Double While More Enter Testing
May/June 2013, Vol. 15 No. 3
SUMMARY | Press Release

Global Site Landscape Remains Highly Fragmented with Variable Performance
March/April 2013, Vol. 15 No. 2
SUMMARY | Press Release

89% of Trials Meet Enrollment, but Timelines Slip, Half of Sites Under-Enroll
January/February 2013, Vol. 15 No. 1
SUMMARY | Press Release


One in Five Procedures Generates Extraneous Clinical Trials Data
November/December 2012, Vol. 14 No. 6
SUMMARY | Press Release

Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in U.S.
September/October 2012, Vol. 14 No. 5
SUMMARY | Press Release

U.S. Offers Patients Faster, Greater Access to Cancer Drugs Than Europe
July/August 2012, Vol. 14 No. 4
SUMMARY | Press Release

User Fee Era in U.S. Currently Poses Mixed Regulatory Burden for Sponsors
May/June 2012, Vol. 14 No. 3
SUMMARY | Press Release

Pace of CNS Drug Development and FDA Approvals Lags Other Drug Classes
March/April 2012, Vol. 14 No. 2
SUMMARY | Press Release

Study Monitor Workload High & Varied with Wide Disparity by Global Region
January/February 2012, Vol. 14 No. 1
SUMMARY | Press Release

2011 - 1999

Tufts CSDD Impact Reports 1999 - 2011 | View Catalog